Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology.

Autor:	Kaufman HW; Quest Diagnostics, Secaucus, New Jersey, USA., Meyer WA; Quest Diagnostics, Secaucus, New Jersey, USA., Clarke NJ; Quest Diagnostics, Secaucus, New Jersey, USA., Radcliff J; Quest Diagnostics, Secaucus, New Jersey, USA., Rank CM; Roche Diagnostics GmbH, Penzberg, Germany., Freeman J; Siemens Healthineers, Tarrytown, New York, USA., Eisenberg M; LabCorp, Burlington, North Carolina, USA., Gillim L; LabCorp, Burlington, North Carolina, USA., Morice WG; Mayo Medical Laboratories, Rochester, Minnesota, USA., Briscoe DM; Boston Children's Hospital, Boston, Massachusetts, USA., Perlin DS; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Wohlgemuth JG; Quest Diagnostics, Secaucus, New Jersey, USA.
Jazyk:	angličtina
Zdroj:	Population health management [Popul Health Manag] 2023 Feb; Vol. 26 (1), pp. 29-36.
DOI:	10.1089/pop.2022.0241
Abstrakt:	Individuals at increased risk for severe coronavirus disease-2019 (COVID-19) outcomes, due to compromised immunity or other risk factors, would benefit from objective measures of vulnerability to infection based on vaccination or prior infection. The authors reviewed published data to identify a specific role and interpretation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike-targeted serology testing. Specific recommendations are provided for an evidence-based and clinically-useful interpretation of SARS-CoV-2 spike-targeted serology to identify vulnerability to infection and potential subsequent adverse outcomes. Decreased vaccine effectiveness among immunocompromised individuals is linked to correspondingly high rates of breakthrough infections. Negative results on SARS-CoV-2 antibody tests are associated with increased risk for subsequent infection. "Low-positive" results on semiquantitative SARS-CoV-2 spike-targeted antibody tests may help identify persons at increased risk as well. Standardized SARS-CoV-2 spike-targeted antibody tests may provide objective information on the risk of SARS-CoV-2 infection and associated adverse outcomes. This holds especially for high-risk populations that demonstrate a relatively high rate of seronegativity. The widespread availability of such tests presents an opportunity to refine risk assessment for individuals with suboptimal SARS-CoV-2 antibody levels and to promote effective interventions. Interim federal guidance would support physicians and patients while additional investigations are pursued.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu